The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes

Summary

It is well-known that women with previous gestational diabetes mellitus are in risk of developing type 2 diabetes later in life; approximately half of the women develop overt type 2 diabetes within the first 10 years after pregnancy. Knowing this, we want to examine the effect of the type 2 diabetes medicine, liraglutide (Victoza), in women with previous gestational diabetes with the aim of reducing the risk of developing type 2 diabetes.

Conditions

• Gestational Diabetes Mellitus

Interventions

DRUG

Liraglutide

1.8 mg liraglutide

DRUG

Placebo

Liraglutide without the GLP-1 analogue

Sponsors & Collaborators

• Novo Nordisk A/S

  collaborator INDUSTRY

• Rigshospitalet, Denmark

  collaborator OTHER

• Hvidovre University Hospital

  collaborator OTHER

• Herlev Hospital

  collaborator OTHER

• Hillerod Hospital, Denmark

  collaborator OTHER

• University of Copenhagen

  collaborator OTHER

• The Novo Nordisk Foundation Center for Basic Metabolic Research

  collaborator OTHER

• Aarhus University Hospital

  collaborator OTHER

• Tina Vilsboll

  lead OTHER

Principal Investigators

• Tina Vilsbøll, MD, DMSc · University Hospital Gentofte

• Signe Foghsgaard, MD, PhD · University Hospital Gentofte

• Emilie Skytte Andersen, MD, PhD-student · Steno Diabetes Center Copenhagen

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

FEMALE

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2012-07-31

Primary Completion

2019-09-30

Completion

2020-09-30

Countries

• Denmark

Study Locations